Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease
NCT00253084
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Parkinson's Disease
Interventions
DRUG:
IPX054 200 mg
DRUG:
CD-LD IR
DRUG:
IPX054 Placebo
DRUG:
CD-LD IR Placebo
Sponsor
Impax Laboratories, LLC